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Game parks in Tanzania have long been considered to be at
low risk for African trypanosomiasis; however, nine cases of the
disease associated with these parks were recently reported.
The outbreak was detected through TropNetEurop, a sentinel
surveillance network of clinical sites throughout Europe.
frican trypanosomiasis (sleeping sickness), a serious
infection caused by a protozoan (Trypanosoma brucei), is
usually spread to humans by the tsetse fly via infected animals
and humans. Although the World Health Organization has
reported a dramatic increase in incidence in Africa, the disease
has remained a rare but well-documented cause of fever in
travelers returning from endemic areas. In recent years, infec-
tion in returning travelers has been more likely to be due to the
East African form (caused by T. brucei rhodesiense), rather
than the West African form (which is due to T. brucei gambi-
ense); the latter form causes a fulminant illness for which rapid
diagnosis is necessary (1,2). We report details of nine recent
cases caused by the West African form of this disease, one
fatal; all of the cases occurred in travelers to Tanzanian
national parks.
Case Reports
Game parks in Tanzania have long been considered to be
low-risk areas for African trypanosomiasis (3). However, in
February 2001, two index patients and seven additional Euro-
pean and South African patients were seen with trypanosomia-
sis acquired in the Tarangire and Serengeti National Parks,
Tanzania (4). The patients were identified and reported in
TropNetEurop, a sentinel surveillance network of clinical sites
throughout Europe for monitoring imported infectious dis-
eases.
All of the South African patients but one were European
nationals (Table). To our knowledge, all patients had traveled
to the Tarangire and Serengeti National Parks, in addition to a
number of other destinations. This area in East Africa has been
implicated as being endemic for African trypanosomiasis.
However, the case incidence in Tanzanian and foreign nation-
als has been very low in recent decades.
During their journey or briefly after their return, the
patients, all febrile, were seen by general practitioners or
emergency departments. Most patients were seen during the
primary stage of disease (patients 1, 3, 4, 6, 7, 8; Table); how-
ever, several showed signs of the secondary stage, including
cerebral manifestations. Most patients also showed a typical
skin lesion, the trypanosome chancre. Diagnosis was estab-
lished by thin and thick blood film. Although three patients
had multiorgan failure, and specific medication was difficult to
obtain, drug treatment proved successful in all but one patient,
who died. Drugs for treatment were not chosen for the clinical
stage the patients exhibited but rather for availability. Thus,
patients with complications and a manifest secondary stage of
disease received pentamidine only.
Conclusions
The temporal clustering of imported cases suggests a
change in the local epidemiology of this disease and may her-
ald further cases in tourists during the current travel season.
For 1998, the World Tourism Organization recorded 450,000
visitors to Tanzania (5), for a potential annual incidence of try-
panosomiasis in tourists to Tanzania of at least 9/450,000. This
is an increase from near zero during recent years to 2/100,000.
The risk for those visiting the Tarangire and Serengeti
National Parks is obviously higher. Reaction of the Tanzanian
authorities involved strengthening installation of insecticide-
impregnated locations in Serengeti to include roads, lodges,
staff quarters, and campsites. This initial program resulted in a
dramatic decline of tsetse flies in Serengeti during the second
half of 2001. This effort will have to be sustained by manda-
tory killing of flies at some keys areas including Serengeti,
Tarangire, and Lake Manyara National Parks. The National
Medical Research Program has been directed to screen more
people for the disease around these foci.
For many of the patients, drugs for treatment were
extremely difficult to obtain. For some European patients,
treatment with suramin was possible only after informal help
from member sites of the network. Drugs for treatment
(suramin, melasoprol, and eflornithin) have now been
obtained. Surveillance in cattle to establish their role in the
epidemiology of the disease will also be conducted (Tanzania
Chief Veterinary Officer, pers. comm.).
This report highlights the effectiveness and importance of
sentinel surveillance methods for monitoring imported infec-
tious diseases in Europe. TropNetEurop, the network that iden-
tified and reported the index cases, is known for its speed of
reporting, often within days of diagnosis. The network’s use of
member sites as regional referral centers is based on an
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anonymous reporting system at sentinel clinics. Discussion of
the index patients by member sites triggered increased aware-
ness within the network and led to the rapid recording of addi-
tional patients and a pattern that might have otherwise gone
undetected.
Dr. Jelinek is consultant for infectious diseases and tropical med-
icine at the Department of Infectious Diseases and Tropical Medicine,
University of Munich. He also coordinates the European Network on
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Table. Patients with African trypanosomiasis, Tanzania 
No. Sex Age Nationality
Mo/yr of
diagnosis Clinical details and treatment Travel historya
1 M 33 Italian 02/01 Skin lesion (back), fever, nausea/vomiting; 
no major complications; treatment with 
suramin
Tourist: Kenya; Lake Manyara, Serengeti, and 
Ngorongoro NPs 
2 M 32 Italian 02/01 Skin lesion left leg; fever; multiorgan fail-
ure; anuria; treatment with pentamidine
Tourist: East Tsavo, Ngorongoro, 
and Serengeti NPs 
3 F 44 British 02/01 Skin lesion left leg; fever; no major compli-
cations; treatment with suramin
Tourist: Nairobi, Amboseli, Lake Manyara, 
Ngorongoro, and Serengeti NPs
4 M 41 Swedish 03/01 Skin lesion right foot; fever; treatment with 
suramin
Tourist: Lake Manyara, Ngorongoro, Tarangire, 
and Serengeti NPs
5 M 68 South African 03/01 Fever; renal failure; acidosis; jaundice; DIC; 
treatment with melasoprol
Tourist: Serengeti NP
6 F 27 Norwegian 03/01 Skin lesion left side of face; fever; no com-
plications; treatment with suramin
Research project on zebras: Ngorongoro and 
Serengeti NPs
7 M 60 Dutch 03/01 Fever; treatment with suramin Tarangire NP
8 F 55 Dutch 04/01 Skin lesion left ankle; fever; headache; treat-
ment with suramin
Tarangire NP
9 F 53 Dutch 06/01 Skin lesion right leg; fever; headache; intrac-
erebral manifestation; coma; death; treat-
ment with suramin and melasoprol
Lake Manyara, Ngorongo, and Serengeti NPs
aEast Tsavo NP and Amboseli NP are in Kenya; all other NPs mentioned are in Tanzania. 
NP, national park; DIC, disseminated intravascular coagulopathy.
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